Effect of Osimertinib in Combination With Chemotherapy and Bevacizumab for Untreated Epidermal Growth Factor Receptor–Mutated Advanced Non-Small-Cell Lung Cancer: Case Report

Introduction: Osimertinib is an oral, third-generation, irreversible epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI) that selectively inhibits both EGFR-TKI–sensitizing and EGFR T790M resistance mutations. However, whether patients with EGFR mutations can be treated by osimerti...

Descripción completa

Detalles Bibliográficos
Autores principales: Qin, Haifeng, Wang, Fang, Zeng, Zhen, Jia, Suting, Liu, Yuan, Gao, Hongjun
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2021
Materias:
Pharmacology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8339960/
https://www.ncbi.nlm.nih.gov/pubmed/34366844
http://dx.doi.org/10.3389/fphar.2021.679667

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8339960/
https://www.ncbi.nlm.nih.gov/pubmed/34366844
http://dx.doi.org/10.3389/fphar.2021.679667

Ejemplares similares